The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp for schizophrenia: A 24-week double blind placebo controlled study
This study is completed in Australia. It focuses on schizophrenia.
SchizophreniaOtherFrom 18 Years to No limit
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What the source says
The registry describes this research topic: “The efficacy of mangosteen pericarp fruit extract for the treatment of schizophrenia”. This is an interventional study. The registry lists a target sample size of 150. Recruitment status at the registry update of 2020-05-19: completed. Read the original description and eligibility criteria, and confirm the practical details with the study team.
What should you check before joining?
Check the full criteria in the official source. Ask the team to confirm recruitment, locations, visits, risks and participation requirements.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateJuly 28, 2016
Recruitment status
Completed
Enrollment listed in the registry
150
Sponsor
University Hospital-Barwon Health
Sponsor type
Hospital / academic medical center
Study type
Other
Intervention type
Treatment: Other
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Australia
Age range
From 18 Years to No limit
Official registry ID
ACTRN12616000859482
Official title
The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp for the treatment of schizophrenia: A 24-week double blind randomised placebo controlled trial
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: ACTRN12616000859482. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Australia · 8 sites
Royal Brisbane & Womens Hospital
Herston
Site status: Not listed — confirm with the team
Ipswich Hospital
Ipswich
Site status: Not listed — confirm with the team
The Prince Charles Hospital
Chermside
Site status: Not listed — confirm with the team
Gold Coast Hospital
Southport
Site status: Not listed — confirm with the team
Logan Hospital
Meadowbrook
Site status: Not listed — confirm with the team
Princess Alexandra Hospital
Woolloongabba
Site status: Not listed — confirm with the team
Barwon Health - Geelong Hospital campus
Geelong
Site status: Not listed — confirm with the team
The Geelong Clinic
St Albans Park
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to No limit. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by University Hospital-Barwon Health, which appears to be a hospital or academic medical center. The listed contact or investigator is Michael Berk. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.